(Prescription attached):-

đŠē āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻ Clinical Diagnostic Assessment
Patient: Fatema Begum | Age: 56 Years
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύāĻāĻŋ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Diagnosis, Examination Findings, Investigations, Treatment Plan āĻāĻŦāĻ āĻāϝāĻŧāĻāĻŋ āĻāώā§āϧā§āϰ Generic Name, MedEx Therapeutic Class, āĻŦā§āϝāĻŦāĻšāĻžāϰ, āĻŽā§āϞā§āϝ āĻ āϰā§āĻā§āĻā§ āĻĻā§āĻāϝāĻŧāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ āύāĻŋāĻā§ āĻŦā§āϝāĻžāĻā§āϝāĻž āĻāϰāĻāĻŋāĨ¤
āϏāĻŦāĻā§āϝāĻŧā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώāϝāĻŧ: āĻāĻŋāĻāĻŋā§āϏāĻ IHD with HTN āϞāĻŋāĻā§āĻā§āύāĨ¤ āϤāĻŦā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϰā§āύāĻžāϰāĻŋ āĻāϰā§āĻāĻžāϰāĻŋāϤ⧠āĻŦā§āϞāĻā§āĻā§āϰ āύāĻŋāĻļā§āĻāĻŋāϤ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤ āĻ āύā§āϝāĻĻāĻŋāĻā§ Echocardiography-āϤ⧠Moderate Concentric Left Ventricular Hypertrophy āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§, āϝāĻž āĻĻā§āϰā§āĻāĻĻāĻŋāύā§āϰ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻāĻžāϰāĻŖā§ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻ āĻāĻžāĻĄāĻŧāĻž āϰā§āĻā§āϰ āϰāĻā§āϤāĻāĻžāĻĒ 95/63 mmHg, āϝāĻž āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻĻā§āĻāϝāĻŧāĻž BP-āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧāĻā§āϞā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
ā§§. Patient History āĻ Chief Complaints (C/C)
| āĻŦāĻŋāώāϝāĻŧ | āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϤāĻĨā§āϝ |
| Patient Name | Fatema Begum |
| Age | 56 Years |
| Prescription Date | 05/01/2026 |
| Chief Complaints (C/C) | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Previous HTN | Diagnosis-āĻ HTN āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§ |
| Previous IHD | Diagnosis-āĻ IHD āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§ |
| Diabetes Mellitus | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Smoking History | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Family History | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Previous MI/PCI/CABG | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Drug Allergy | āĻāϞā§āϞā§āĻ āύā§āĻ |
Clinical Interpretation:
āĻāĻŋāĻāĻŋā§āϏāĻ āϰā§āĻā§āϰ IHD āĻāĻŦāĻ HTN āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤ āĻāĻŋāύā§āϤ⧠āĻŦā§āĻā§ āĻŦā§āϝāĻĨāĻž, āĻļā§āĻŦāĻžāϏāĻāώā§āĻ, āĻĒāϰāĻŋāĻļā§āϰāĻŽā§ āĻŦā§āĻāĻŦā§āϝāĻĨāĻž, āĻāϤāĻĻāĻŋāύ āϧāϰ⧠āĻāĻĒāϏāϰā§āĻ, āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻšāĻžāϰā§āĻ āĻ ā§āϝāĻžāĻāĻžāĻ āĻāĻŋāĻāĻŦāĻž Coronary Angiography-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāϞā§āϞā§āĻ āĻāϰā§āύāύāĻŋāĨ¤
āϏā§āϤāϰāĻžāĻ āĻāĻā§āϞā§āĻā§ Documented Clinical Diagnosis āĻŦāϞāĻž āϝāĻžāϝāĻŧ, āĻāĻŋāύā§āϤ⧠āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻšāĻŋāϏā§āĻŦā§ āϧāϰ⧠āύā§āĻāϝāĻŧāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.99 â āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞā§āϞāĻŋāĻāĻŋāϤ āϤāĻĨā§āϝā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤā§āĨ¤
⧍. On Examination (O/E)
| Examination | Result | Interpretation |
| Blood Pressure | 95/63 mmHg | āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻāĻŽ |
| Pulse | 74 beats/min | āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ resting pulse range |
| Respiratory Rate | āĻāϞā§āϞā§āĻ āύā§āĻ | āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
| SpOâ | āĻāϞā§āϞā§āĻ āύā§āĻ | āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
| Chest Examination | āĻāϞā§āϞā§āĻ āύā§āĻ | āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
| Cardiac Auscultation | āĻāϞā§āϞā§āĻ āύā§āĻ | āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
Clinical Significance
BP 95/63 mmHg
āϰā§āĻā§āϰ HTN-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāϞā§āĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻŽāϝāĻŧ āϰāĻā§āϤāĻāĻžāĻĒ āĻŦā§āĻļāĻŋ āĻāĻŋāϞ āύāĻžāĨ¤
āϰā§āĻā§āĻā§ āϤāĻŋāύāĻāĻŋ BP-āĻāĻŽāĻžāύā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāϝā§āĻā§āϤ āĻāώā§āϧ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§:
- Olmesartan
- Metoprolol
- Nitroglycerin
āĻāĻā§āϞā§āϰ āϏāĻŽā§āĻŽāĻŋāϞāĻŋāϤ āĻĒā§āϰāĻāĻžāĻŦā§ Hypotension āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ 95/63 mmHg-āĻāϰ āĻāĻāĻāĻŋ āϰāĻŋāĻĄāĻŋāĻ āĻĨā§āĻā§āĻ āϰā§āĻā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ Hypotensive āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤ āϰā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ, āĻāĻā§āϰ BP āĻāĻŦāĻ āĻĒā§āύāϰāĻžāϝāĻŧ BP āĻŽāĻžāĻĒāĻžāϰ āĻĢāϞ āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Clinical Recommendation: āϰā§āĻā§ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻāϏāĻŦ āĻāώā§āϧ āĻā§āϞ⧠BP āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āĻāĻŦāĻ āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž, āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻŦāĻž āĻ āĻā§āĻāĻžāύ āĻšāĻāϝāĻŧāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāϞ⧠āĻĻā§āϰā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻĄā§āĻ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āύāĻŋāĻā§ āĻĨā§āĻā§ Metoprolol āĻŦāĻž āĻ āύā§āϝ āĻā§āύ⧠āĻāώā§āϧ āĻšāĻ āĻžā§ āĻŦāύā§āϧ āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
ā§Š. Doctor’s Diagnosis (Dx)
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āϞāĻŋāĻā§āĻā§āύ:
IHD WITH HTN
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ:
āĻāϏā§āĻā§āĻŽāĻŋāĻ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āϏāĻā§āĻā§ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒāĨ¤
A. IHD â Ischemic Heart Disease
Definition: āĻāϰā§āύāĻžāϰāĻŋ āϰāĻā§āϤāύāĻžāϞāĻŋāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻšā§āĻĻā§âāĻĒā§āĻļāĻŋāϰ āĻ āĻā§āϏāĻŋāĻā§āύā§āϰ āĻāĻžāĻšāĻŋāĻĻāĻž āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĒāϰā§āϝāĻžāĻĒā§āϤ āϰāĻā§āϤ āϏāϰāĻŦāϰāĻžāĻš āύāĻž āĻšāϞ⧠Myocardial Ischemia āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϏāĻžāϧāĻžāϰāĻŖ āĻāĻžāϰāĻŖ āĻšāϞ⧠Coronary Atherosclerosis, āϤāĻŦā§ Coronary Microvascular Dysfunction āĻŦāĻž Coronary Vasospasm-āĻāϰ āĻāĻžāϰāĻŖā§āĻ Ischemia āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĒāϏāϰā§āĻ:
- āĻŦā§āĻā§ āĻāĻžāĻĒ āĻŦāĻž āĻŦā§āϝāĻĨāĻž
- āĻĒāϰāĻŋāĻļā§āϰāĻŽā§ āĻŦā§āĻā§ āĻ āϏā§āĻŦāϏā§āϤāĻŋ
- āĻļā§āĻŦāĻžāϏāĻāώā§āĻ
- āĻŦā§āϝāĻĨāĻž āĻŦāĻžāĻŽ āĻšāĻžāϤ, āĻā§āϝāĻŧāĻžāϞ āĻŦāĻž āĻĒāĻŋāĻ ā§ āĻāĻĄāĻŧāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž
āĻāĻ āĻāĻĒāϏāϰā§āĻāĻā§āϞ⧠āϰā§āĻā§āϰ āĻāĻā§ āĻŦāϞ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
B. HTN â Hypertension
Definition: āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒāĨ¤
āĻĻā§āϰā§āĻāĻĻāĻŋāύ HTN āĻĨāĻžāĻāϞ⧠Left Ventricle-āĻāϰ āĻĻā§āϝāĻŧāĻžāϞ āĻĒā§āϰ⧠āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻāĻāĻŋāĻā§ Left Ventricular Hypertrophy (LVH) āĻŦāϞāĻž āĻšāϝāĻŧāĨ¤
āĻāĻ āϰā§āĻā§āϰ Echo-āϤ⧠LVH āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§āĨ¤
ā§Ē. Investigation Report Analysis
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻĒāĻžāĻāĻāĻāĻŋ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§āĨ¤
| Investigation | Report | Clinical Interpretation |
| Echo 2D | LVEF 69% | LV systolic function preserved |
| Regional Wall Motion | No RWMA at rest | āĻŦāĻŋāĻļā§āϰāĻžāĻŽ āĻ āĻŦāϏā§āĻĨāĻžāϝāĻŧ āĻĻā§āϝāĻŧāĻžāϞā§āϰ āĻāĻā§āĻāϞāĻŋāĻ āϏāĻāĻā§āĻāύ⧠āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāϤāĻž āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋ |
| LV Structure | Moderate Concentric LVH | āĻŦāĻžāĻŽ āĻā§āύā§āĻā§āϰāĻŋāĻāϞā§āϰ āĻĻā§āϝāĻŧāĻžāϞ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āĻĒā§āϰ⧠|
| Chamber Dimensions | Within normal limits | āĻā§āĻŽā§āĻŦāĻžāϰā§āϰ āĻŽāĻžāĻĒ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ |
| RBG | 4.7 | āĻāĻāĻ āĻĻā§āĻāϝāĻŧāĻž āύā§āĻ; mmol/L āĻšāϞ⧠āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻā§āϰ āĻŽāϧā§āϝ⧠|
| Serum Creatinine | 1.1 | āĻāĻāĻ āĻ eGFR āĻāĻžāĻĄāĻŧāĻž āĻĒā§āϰā§āĻŖ renal assessment āϏāĻŽā§āĻāĻŦ āύāϝāĻŧ |
| Troponin I | <0.006 | āĻĒāϰā§āĻā§āώāĻžāϰ reference range āĻ unit āĻĒā§āϰāϝāĻŧā§āĻāύ |
| CXR (P/A) | Cardiomegaly | X-ray-āϤ⧠āĻšā§āĻĻā§âāϝāύā§āϤā§āϰ āĻŦāĻĄāĻŧ āĻĻā§āĻāĻž āĻā§āĻā§ |
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Echocardiography Findings
1. LVEF = 69%
Left Ventricular Ejection Fraction āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āϏā§āĻŽāĻžāϝāĻŧ āϰāϝāĻŧā§āĻā§āĨ¤
āĻāĻāĻŋ āύāĻŋāϰā§āĻĻā§āĻļ āĻāϰ⧠āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻŦāĻžāĻŽ āĻā§āύā§āĻā§āϰāĻŋāĻāϞā§āϰ Systolic Pumping Function āϏāĻāϰāĻā§āώāĻŋāϤāĨ¤
Confidence: 0.99
2. Moderate Concentric LV Hypertrophy
āĻāĻāĻŋ āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ abnormal findingāĨ¤
Concentric LVH-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻŦāĻžāĻŽ āĻā§āύā§āĻā§āϰāĻŋāĻāϞā§āϰ āĻĻā§āϝāĻŧāĻžāϞ āĻĒā§āϰ⧠āĻšāϝāĻŧāĨ¤
āĻĻā§āϰā§āĻāĻĻāĻŋāύā§āϰ Hypertension āĻāϰ āĻāĻāĻāĻŋ āϏāĻžāϧāĻžāϰāĻŖ āĻāĻžāϰāĻŖāĨ¤
Working interpretation: Hypertensive Heart Disease with LVH.
Confidence: 0.85 â HTN āĻāϤāĻŋāĻšāĻžāϏ āĻ Echo findings āĻāĻāϏāĻā§āĻā§ āĻāĻ āĻŦā§āϝāĻžāĻā§āϝāĻžāĻā§ āϏāĻŽāϰā§āĻĨāύ āĻāϰā§; āĻ āύā§āϝ āĻāĻžāϰāĻŖ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻŦāĻžāĻĻ āϝāĻžāϝāĻŧāύāĻŋāĨ¤
3. No RWMA at Rest
āĻŦāĻŋāĻļā§āϰāĻžāĻŽ āĻ āĻŦāϏā§āĻĨāĻžāϝāĻŧ āĻā§āύ⧠Regional Wall Motion Abnormality āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
āϤāĻŦā§ āĻāϰ āĻ āϰā§āĻĨ āĻāĻ āύāϝāĻŧ āϝ⧠Coronary Artery Disease āύā§āĻāĨ¤
Resting Echo āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĨāĻžāĻāϞā§āĻ Significant CAD āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
4. Cardiomegaly
CXR-āϤ⧠āĻšā§āĻĻā§âāϝāύā§āϤā§āϰ āĻŦāĻĄāĻŧ āĻĻā§āĻāĻž āĻā§āĻā§āĨ¤
āĻāĻāĻŋ Echo-āϤ⧠āĻĒāĻžāĻāϝāĻŧāĻž LVH-āĻāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ X-ray-āϤ⧠Cardiomegaly āĻŽāĻžāύā§āĻ Heart Failure āύāϝāĻŧāĨ¤
5. Troponin I <0.006
āĻāĻāĻāĻŋ Troponin result āĻĻāĻŋāϝāĻŧā§ Acute Coronary Syndrome āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
āĻāϰ āĻāύā§āϝ āĻāĻĒāϏāϰā§āĻ, ECG, āĻĒāϰā§āĻā§āώāĻžāϰ reference limit āĻāĻŦāĻ āĻĒā§āϰāϝāĻŧā§āĻāύ⧠serial high-sensitivity troponin āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Cardiomegaly āĻā§ āĻāĻŦāĻ āĻā§āύ āĻšāϝāĻŧ?
Cardiomegaly (āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻāĻāĻžāϰ āĻŦā§āĻĻā§āϧāĻŋ) āĻšāϞ⧠āĻšā§āĻĻā§âāϝāύā§āϤā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻā§āϰ āϤā§āϞāύāĻžāϝāĻŧ āĻŦāĻĄāĻŧ āĻšāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤ āĻāĻāĻŋ āύāĻŋāĻā§ āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻ āύāϝāĻŧ; āĻŦāϰāĻ āĻāĻāĻāĻŋ Clinical/Radiological FindingāĨ¤
ā§§. āĻā§āύ āĻšāϝāĻŧ? (Etiology)
- Hypertension (HTN): āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒ āĻĨāĻžāĻāϞ⧠āĻšāĻžāϰā§āĻāĻā§ āĻŦā§āĻļāĻŋ āĻāĻžāĻĒā§āϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠āϰāĻā§āϤ āĻĒāĻžāĻŽā§āĻĒ āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤
- Ischemic Heart Disease (IHD): āĻšā§āĻĻā§âāĻĒā§āĻļāĻŋāϤ⧠āϰāĻā§āϤ āϏāϰāĻŦāϰāĻžāĻš āĻāĻŽā§ āĻāĻŋāϝāĻŧā§ āĻā§āώāϤāĻŋ āĻšāϞ⧠āĻšāĻžāϰā§āĻ āĻŦāĻĄāĻŧ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Cardiomyopathy: āĻšā§āĻĻā§âāĻĒā§āĻļāĻŋāϰ āĻāĻ āύ āĻŦāĻž āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻžāϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĨ¤
- Valvular Heart Disease: āĻšāĻžāϰā§āĻā§āϰ āĻāĻžāϞāĻā§āϰ āϏāĻŽāϏā§āϝāĻžāϝāĻŧ āĻāĻžāĻĒ āĻŦāĻž āϰāĻā§āϤā§āϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻŦā§āĻĄāĻŧā§ āϝāĻžāϝāĻŧāĨ¤
⧍. āĻā§āĻāĻžāĻŦā§ āĻšāϝāĻŧ? (Pathophysiology)
Chronic HTN â Increased Afterload â LV Wall Thickening (LVH) â Cardiac Remodeling â Cardiomegaly
āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻ āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŋāϤ āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻā§ āϰā§āĻā§āϰ Diastolic Dysfunction āĻāĻŦāĻ āĻĒāϰāĻŦāϰā§āϤ⧠āϏāĻŽāϝāĻŧā§ Heart Failure āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
ā§Š. āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻā§āύ āĻšāϝāĻŧā§āĻā§?
āϰā§āĻā§āϰ āϰāĻŋāĻĒā§āϰā§āĻ āĻ āύā§āϝāĻžāϝāĻŧā§:
- HTN: āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āϰāϝāĻŧā§āĻā§āĨ¤
- Echo: Moderate Concentric LVH āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§āĨ¤
- CXR: Cardiomegaly āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§āĨ¤
- LVEF: 69% â āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ Systolic FunctionāĨ¤
â Most Likely Cause: āĻĻā§āϰā§āĻāĻĻāĻŋāύā§āϰ Hypertension-āĻāϰ āĻāĻžāϰāĻŖā§ Hypertensive Cardiac Remodeling/LVHāĨ¤
Clinical Confidence: 85% â āĻāĻāĻŋ āϏāĻŦāĻā§āϝāĻŧā§ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ āĻŦā§āϝāĻžāĻā§āϝāĻž, āϤāĻŦā§ CXR-āϤ⧠Cardiomegaly āĻĻā§āĻāĻž āĻā§āϞā§āĻ āĻĒā§āϰāĻā§āϤ Heart Enlargement āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϝāĻŧ āύāĻžāĨ¤
ā§Ē. āĻāĻŋāĻāĻŋā§āϏāĻž āĻā§?
āĻŽā§āϞāϤ āĻāĻžāϰāĻŖ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻŋāĻāĻŋā§āϏāĻž:
- BP āύāĻŋāϰāĻžāĻĒāĻĻ āϏā§āĻŽāĻžāϝāĻŧ āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖāĨ¤
- āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ Antihypertensive MedicationāĨ¤
- Salt Intake āĻāĻŽāĻžāύ⧠āĻāĻŦāĻ Cardiovascular Risk Factors āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖāĨ¤
- Echo āĻ Clinical Follow-upāĨ¤
āĻāĻ āϰā§āĻā§āϰ BP 95/63 mmHg āĻšāĻāϝāĻŧāĻžāϝāĻŧ BP-āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧā§āϰ āĻĄā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
đ References
- Harrison’s Principles of Internal Medicine, 22nd Edition â Hypertension and Heart Disease.
- Braunwald’s Heart Disease, 12th Edition â Cardiac Remodeling and Hypertrophy.
- 2024 ESC Hypertension Guidelines.
Final Clinical Interpretation:
Cardiomegaly on CXR, likely related to Hypertensive Heart Disease with Moderate Concentric LVH and Preserved LVEF (69%).
āĻŦāĻžāĻāϞāĻž: āĻĻā§āϰā§āĻāĻĻāĻŋāύā§āϰ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻĒā§āϰāĻāĻžāĻŦā§ āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻŦāĻžāĻŽ āĻā§āύā§āĻā§āϰāĻŋāĻāϞā§āϰ āĻĻā§āϝāĻŧāĻžāϞ āĻĒā§āϰ⧠āĻšāϝāĻŧā§āĻā§, āϝāĻžāϰ āϏāĻā§āĻā§ X-ray-āϤ⧠āĻšā§āĻĻā§âāϝāύā§āϤā§āϰ āĻŦāĻĄāĻŧ āĻĻā§āĻāĻžāύā§āϰ āϏāĻŽā§āĻĒāϰā§āĻ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
ā§Ģ. Doctor’s Advice / Treatment Plan
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§:
CAG â Coronary Angiography
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āύāĻžāϰāĻŋ āĻāύāĻāĻŋāĻāĻā§āϰāĻžāĻĢāĻŋāĨ¤
āĻā§āύ āĻāĻŋāĻāĻŋā§āϏāĻ CAG āĻāϰāĻžāϰ āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž āĻāϰā§āĻā§āύ?
āϏāĻŽā§āĻāĻŦāϤ āĻāĻŋāĻāĻŋā§āϏāĻ āĻāϰā§āύāĻžāϰāĻŋ āϰāĻā§āϤāύāĻžāϞāĻŋāϤ⧠āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āϏāĻāĻā§āĻāύ āĻŦāĻž āĻŦā§āϞāĻā§āĻ āĻāĻā§ āĻāĻŋ āύāĻž āϤāĻž āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāϤ⧠āĻāĻžāύāĨ¤
CAG-āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§:
- Coronary Artery Stenosis
- Significant Coronary Obstruction
- Multivessel Coronary Disease
āĻāϤā§āϝāĻžāĻĻāĻŋ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤
Guidelines āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ
2024 ESC Chronic Coronary Syndrome Guideline āĻ āύā§āϝāĻžāϝāĻŧā§, āĻā§āĻŦ āĻŦā§āĻļāĻŋ CAD likelihood, āĻā§āϰā§āϤāϰ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āύāĻž-āĻāĻŽāĻž Angina, āĻ āϞā§āĻĒ āĻĒāϰāĻŋāĻļā§āϰāĻŽā§ āĻāĻĒāϏāϰā§āĻ āĻāĻŋāĻāĻŦāĻž āĻāĻā§āĻ āĻā§āĻāĻāĻŋāϰ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞ āĻĨāĻžāĻāϞ⧠Invasive Coronary Angiography āĻāĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻāĻŽ āĻŦāĻž āĻŽāϧā§āϝāĻŽ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāϰ āϰā§āĻā§āĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻĒāϏāϰā§āĻ āĻ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻā§ CCTA āĻŦāĻž Functional Imaging āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšāϝāĻŧāĨ¤
āĻāĻ āϰā§āĻā§āϰ CAG-āĻāϰ āϝāĻĨāĻžāϰā§āĻĨāϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠Chief Complaints, ECG āĻāĻŦāĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Ischemia Testing āĻāĻžāύāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
ā§Ŧ. Prescription Drug Analysis â MedEx āĻ āύā§āϝāĻžāϝāĻŧā§Â ***(Medicine Analysis according to Prescription)***
***1. TAB. ECOSPRIN 75 MG***
Generic Name: Aspirin 75 mg
Bangladesh Brand Name: Ecosprin 75 mg
Manufacturer: ACME Laboratories Ltd.
MedEx Therapeutic Class: Anti-platelet drugs
Pharmacological Class: Irreversible COX-1 inhibitor; Antiplatelet agent.
Prescription Dose: 0+1+0 â āĻĻā§āĻĒā§āϰ⧠āĻāĻžāĻŦāĻžāϰā§āϰ āĻĒāϰ⧠⧧āĻāĻŋāĨ¤
Duration: āĻāϞāĻŦā§āĨ¤
Unit Price: ā§ŗ0.80
Strip Price: ā§ŗ11.20 (14 Tablets)
Use of Purpose the Drug
Aspirin 75 mg āĻŽā§āϞāϤ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ:
- Confirmed Coronary Artery Disease
- Previous Myocardial Infarction
- Secondary Prevention of Ischemic Stroke/TIA
- Selected patients after PCI/Stent
- Selected patients after CABG
Why Doctor Prescribed This Drug in This Patient
āĻāĻŋāĻāĻŋā§āϏāĻ IHD āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤
āϤāĻžāĻ āϏāĻŽā§āĻāĻŦāϤ Coronary Thrombotic Event-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠Aspirin āĻĻāĻŋāϝāĻŧā§āĻā§āύāĨ¤
Aspirin Platelet Aggregation āĻāĻŽāĻŋāϝāĻŧā§ āϰāĻā§āϤ āĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻžāϰ āĻĒā§āϰāĻŦāĻŖāϤāĻž āĻāĻŽāĻžāϝāĻŧāĨ¤
Important: Aspirin āĻāϰā§āύāĻžāϰāĻŋ āĻŦā§āϞāĻā§āĻ āĻĻā§āϰ āĻāϰ⧠āύāĻžāĨ¤ āύāĻŋāĻļā§āĻāĻŋāϤ Atherosclerotic CAD āύāĻž āĻĨāĻžāĻāϞ⧠āĻāĻŦāĻ āĻāĻā§ MI, PCI āĻŦāĻž Stroke-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āύāĻž āĻĨāĻžāĻāϞ⧠āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ Aspirin-āĻāϰ benefitâbleeding risk āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Other Available Strength: Ecosprin 81 mgāĨ¤
Alternative Bangladesh Brands: Cardoprin 75 mg, Carva 75 mg, Erasprin 75 mgāĨ¤
MedEx Link: Ecosprin 75 mg
***2. TAB. OLMESAN 20 MG***
Generic Name: Olmesartan Medoxomil 20 mg
Brand Name: Olmesan 20 mg
Manufacturer: Beximco Pharmaceuticals Ltd.
MedEx Therapeutic Class: Angiotensin-II receptor blocker
Pharmacological Class: Angiotensin II ATâ Receptor Antagonist (ARB)
Prescription Dose: 0+0+1 â āϰāĻžāϤ⧠āĻāĻžāĻŦāĻžāϰā§āϰ āĻĒāϰ⧠⧧āĻāĻŋāĨ¤
Duration: āĻāϞāĻŦā§āĨ¤
Unit Price: ā§ŗ10.00
Strip Price: ā§ŗ150.00 (15 Tablets)
Use of Purpose the Drug
Olmesartan āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ:
- Essential Hypertension
- Blood Pressure Control in patients with cardiovascular risk
- Selected patients requiring RAAS blockade
Why Doctor Prescribed This Drug in This Patient
āϰā§āĻā§āϰ HTN āϰāϝāĻŧā§āĻā§āĨ¤
Olmesartan Angiotensin II-āĻāϰ ATâ receptor block āĻāϰ⧠Vasoconstriction āĻāĻŽāĻžāϝāĻŧ āĻāĻŦāĻ āϰāĻā§āϤāĻāĻžāĻĒ āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖā§ āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
Clinical Concern: āϰā§āĻā§āϰ BP 95/63 mmHgāĨ¤ āϤāĻžāĻ Olmesartan-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧāϤāĻž āĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻĄā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻāĻā§ āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§, āĻŦāĻŋāĻļā§āώāϤ āϰā§āĻā§āϰ āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻŦāĻž āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻĨāĻžāĻāϞā§āĨ¤
Monitoring: BP, Serum Creatinine, eGFR āĻ Serum PotassiumāĨ¤
Other Available Strengths: 10 mg, 40 mgāĨ¤
Alternative Bangladesh Brands: Olmesta 20 mg, Olmetab 20 mg, Olmetic 20 mgāĨ¤
MedEx Link: Olmesan 20 mg
***3. TAB. NIDOCARD RETARD 2.6 MG***
Generic Name: Nitroglycerin 2.6 mg
Brand Name: Nidocard Retard 2.6 mg
Manufacturer: Drug International Ltd.
MedEx Therapeutic Class: Nitrates: Coronary vasodilators
Pharmacological Class: Organic Nitrate; Nitric Oxide DonorāĨ¤
Prescription Dose: 1+0+1 â āϏāĻāĻžāϞ⧠āĻ āϰāĻžāϤ⧠⧧āĻāĻŋāĨ¤
Duration: āĻāϞāĻŦā§āĨ¤
Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ70.00 (14 Tablets)
Use of Purpose the Drug
Nitroglycerin āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ:
- Angina Pectoris
- Stable Angina Prophylaxis
- Symptomatic Myocardial Ischemia
- Acute Angina Relief â āĻĻā§āϰā§āϤ āĻāĻžāϰā§āϝāĻāϰ Sublingual formulation
Why Doctor Prescribed This Drug in This Patient
āĻāĻŋāĻāĻŋā§āϏāĻ IHD āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤
āϏāĻŽā§āĻāĻŦāϤ Anginal Chest Pain āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻāώā§āϧāĻāĻŋ āĻĻāĻŋāϝāĻŧā§āĻā§āύāĨ¤
Nitroglycerin āĻĒā§āϰāϧāĻžāύāϤ Venodilation āĻāĻāĻŋāϝāĻŧā§ Cardiac Preload āĻāĻŽāĻžāϝāĻŧ, āĻĢāϞ⧠Myocardial Oxygen Demand āĻāĻŽāϤ⧠āĻĒāĻžāϰā§āĨ¤
Important Clinical Point: Nidocard Retard 2.6 mg āĻšāϞ⧠Sustained-release formulationāĨ¤ āĻāĻāĻŋ āĻšāĻ āĻžā§ āϤā§āĻŦā§āϰ āĻŦā§āĻā§ āĻŦā§āϝāĻĨāĻž āĻšāϞ⧠Sublingual Nitroglycerin-āĻāϰ āĻŦāĻŋāĻāϞā§āĻĒ āύāϝāĻŧāĨ¤
āϰā§āĻā§āϰ BP āĻāĻŽ āĻĨāĻžāĻāĻžāϝāĻŧ Nitrate-induced Hypotension-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ Nitrate āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠Tolerance āĻāĻĄāĻŧāĻžāϤ⧠dosing interval-āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Other Available Strength: Nidocard Retard 6.4 mgāĨ¤
Other Formulations: Nitroglycerin 0.5 mg sublingual tablet āĻ 400 mcg/sprayāĨ¤
Alternative Bangladesh Brands: Anril SR 2.6 mg, Nitrin SR 2.6 mg, GTN SR 2.6 mgāĨ¤
MedEx Link: Nidocard Retard 2.6 mg
***4. TAB. BETALOC 25 MG***
Generic Name: Metoprolol Tartrate 25 mg
Brand Name: Betaloc 25 mg
Manufacturer: Drug International Ltd.
MedEx Therapeutic Class: āĻāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ Brand Page-āĻ āĻĒā§āĻĨāĻ Therapeutic Class label āύā§āĻ; āĻāĻāĻŋ Beta-blocker group-āĻāϰ āĻāώā§āϧāĨ¤
Pharmacological Class: Selective βâ-Adrenergic Receptor BlockerāĨ¤
Prescription Dose: 1+0+1 â āϏāĻāĻžāϞ⧠āĻ āϰāĻžāϤ⧠⧧āĻāĻŋāĨ¤
Duration: āĻāϞāĻŦā§āĨ¤
Unit Price: ā§ŗ1.55
Strip Price: ā§ŗ21.70 (14 Tablets)
Use of Purpose the Drug
Metoprolol āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ:
- Hypertension
- Chronic Stable Angina
- Selected Tachyarrhythmias
- Myocardial Infarction-āĻāϰ āĻĒāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āĻĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ
- Hyperthyroidism-āĻāϰ āĻāĻŋāĻā§ āĻāĻĒāϏāϰā§āĻ āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖā§
Why Doctor Prescribed This Drug in This Patient
āϏāĻŽā§āĻāĻŦāϤ āĻĻā§āĻāĻŋ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻāώā§āϧāĻāĻŋ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§:
āĻĒā§āϰāĻĨāĻŽāϤ: āϰā§āĻā§āϰ Hypertension āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖāĨ¤
āĻĻā§āĻŦāĻŋāϤā§āϝāĻŧāϤ: Suspected IHD-āĻāϰ āĻā§āώā§āϤā§āϰ⧠Heart Rate āĻ Myocardial Oxygen Demand āĻāĻŽāĻžāύā§āĨ¤
Metoprolol βâ receptor block āĻāϰ⧠Heart Rate āĻāĻŦāĻ Myocardial Contractility āĻāĻŽāĻžāϝāĻŧāĨ¤
Clinical Concern: āϰā§āĻā§āϰ Pulse 74 bpm āĻšāϞā§āĻ BP 95/63 mmHgāĨ¤ āϤāĻžāĻ āĻāώā§āϧāĻāĻŋāϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻĄā§āĻ āĻ āϏāĻšāύāĻļā§āϞāϤāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āĻāϰā§āϰāĻŋāĨ¤
LVEF 69% āĻāĻŦāĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠MI-āĻāϰ āϤāĻĨā§āϝ āύāĻž āĻĨāĻžāĻāĻžāϝāĻŧ, āĻļā§āϧā§āĻŽāĻžāϤā§āϰ IHD-āĻāϰ āĻāύā§āϝ Metoprolol āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻā§ cardiovascular outcome āĻāύā§āύāϤ āĻāϰāĻŦā§âāĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻāϝāĻŧāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ āϤāĻŦā§ Angina āĻŦāĻž āĻ āύā§āϝ āĻāĻĒāϝā§āĻā§āϤ indication āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āϝā§āĻā§āϤāĻŋāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Other Available Strength: Betaloc 50 mgāĨ¤
Other Formulation: Betaloc-XR 50 mg āĻ 100 mgāĨ¤ XR formulation-āĻā§ āϏāĻžāϧāĻžāϰāĻŖ Betaloc-āĻāϰ āϏāĻā§āĻā§ āϏāϰāĻžāϏāϰāĻŋ āϏāĻŽāϤā§āϞā§āϝ āϧāϰ⧠āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Alternative Bangladesh Brands: Betaone 25 mg, Selomet 25 mgāĨ¤
MedEx Link: Betaloc 25 mg
***5. TAB. ATV 10 MG***
Generic Name: Atorvastatin Calcium 10 mg
Brand Name: ATV 10 mg
Manufacturer: Delta Pharma PLC.
MedEx Therapeutic Class: Other Anti-anginal & Anti-ischaemic drugs, Statins
Pharmacological Class: HMG-CoA Reductase InhibitorāĨ¤
Prescription Dose: 0+0+1 â āϰāĻžāϤ⧠⧧āĻāĻŋāĨ¤
Duration: āĻāϞāĻŦā§āĨ¤
Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00 (10 Tablets)
Use of Purpose the Drug
Atorvastatin āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ:
- Hypercholesterolemia
- Mixed Dyslipidemia
- Established Atherosclerotic Cardiovascular Disease
- Cardiovascular Risk Reduction
- Secondary Prevention following MI or certain ischemic events
Why Doctor Prescribed This Drug in This Patient
IHD āϏāύā§āĻĻā§āĻš āĻŦāĻž āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧā§āϰ āĻāĻžāϰāĻŖā§ āĻāĻŋāĻāĻŋā§āϏāĻ āϏāĻŽā§āĻāĻŦāϤ cardiovascular risk āĻāĻŽāĻžāϤ⧠āĻĻāĻŋāϝāĻŧā§āĻā§āύāĨ¤
Atorvastatin LDL Cholesterol āĻāĻŽāĻžāϝāĻŧ āĻāĻŦāĻ Atherosclerotic Plaque Stabilization-āĻ āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
Important: āϰā§āĻā§āϰ Lipid Profile āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
Confirmed Chronic Coronary Disease āĻĨāĻžāĻāϞ⧠Guideline āĻ āύā§āϝāĻžāϝāĻŧā§ āĻ āϧāĻŋāĻāĻžāĻāĻļ āĻāĻĒāϝā§āĻā§āϤ āϰā§āĻā§āϰ āĻāύā§āϝ High-intensity Statin āĻŦāĻŋāĻŦā§āĻāĻŋāϤ āĻšāϝāĻŧāĨ¤ Atorvastatin 10 mg āĻāĻāĻāĻŋ Moderate-intensity dose; āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ intensity āύāĻŋāϰā§āϧāĻžāϰāĻŖā§āϰ āĻāύā§āϝ LDL-C, tolerance āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Other Available Strengths: ATV 20 mg, 40 mgāĨ¤
Alternative Bangladesh Brands: Atova 10 mg, Anzitor 10 mg, Avas 10 mgāĨ¤
MedEx Link: ATV 10 mg
***6. TAB. MAXPRO MUPS 20 MG***
Generic Name: Esomeprazole 20 mg
Brand Name: Maxpro MUPS 20 mg
Manufacturer: Renata PLCāĨ¤
MedEx Therapeutic Class: Proton Pump Inhibitor
Pharmacological Class: Gastric Hâē/Kâē-ATPase InhibitorāĨ¤
Prescription Dose: 1+0+1 â āϏāĻāĻžāϞ⧠āĻ āϰāĻžāϤ⧠āĻāĻžāĻŦāĻžāϰā§āϰ āĻāĻā§ ā§§āĻāĻŋāĨ¤
Duration: ā§§ āĻŽāĻžāϏāĨ¤
Unit Price: ā§ŗ10.00
Strip Price: ā§ŗ140.00 (14 Tablets)
Use of Purpose the Drug
Esomeprazole āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ:
- GERD
- Gastritis-āĻāϰ āĻāĻŋāĻā§ Acid-related Symptoms
- Peptic Ulcer Disease
- Erosive Esophagitis
- Selected patients requiring GI protection while using NSAIDs or Antiplatelet therapy
Why Doctor Prescribed This Drug in This Patient
āϏāĻŽā§āĻāĻŦāϤ Aspirin āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŽāϝāĻŧ Gastrointestinal Complication-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
āϤāĻŦā§ āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Ulcer āĻŦāĻž GI Bleeding-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤ āϤāĻžāĻ PPI āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āĻĻāĻŋāύ⧠āĻĻā§āĻāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϝā§āĻā§āϤāĻŋāĻāϤāĻž āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻā§āĻāĻāĻŋāϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Other Available Strength: Maxpro MUPS 40 mgāĨ¤
Alternative Bangladesh Brands: Nexum MUPS 20 mg, Nexpro MUPS 20 mg, Maxima MUPS 20 mgāĨ¤
MedEx Link: Maxpro MUPS 20 mg
ā§. Bangladesh Doctors āϏāĻžāϧāĻžāϰāĻŖāϤ IHD with HTN-āĻ āĻā§āύ āĻā§āύ Drug āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰā§āύ?
āϰā§āĻā§āϰ āϧāϰāύ, Angina-āĻāϰ āĻāĻĒāϏā§āĻĨāĻŋāϤāĻŋ, BP, Heart Rate, Coronary Anatomy āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāώā§āϧ āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
āύāĻŋāĻā§āϰ āϤāĻžāϞāĻŋāĻāĻžāĻāĻŋ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻŦāĻŋāĻāϞā§āĻĒ, āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āύāϤā§āύ Prescription āύāϝāĻŧāĨ¤
| Drug Class | Generic / Bangladesh Brand Example | āĻā§āύ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšāϝāĻŧ |
| Antiplatelet | Aspirin â Ecosprin, Cardoprin | Confirmed Atherosclerotic CAD-āϤ⧠Thrombotic Event Prevention |
| P2Y12 Inhibitor | Clopidogrel â Clopid, Clopilet | āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ CAD, ACS āĻŦāĻž PCI āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠|
| Statin | Atorvastatin â ATV, Atova | LDL āĻāĻŽāĻžāύ⧠āĻ Cardiovascular Risk Reduction |
| High-intensity Statin Option | Rosuvastatin â Rosuva | āĻāĻĒāϝā§āĻā§āϤ āϰā§āĻā§āϰ LDL Reduction āĻ Secondary Prevention |
| ARB | Olmesartan â Olmesan, Olmesta | Hypertension Control |
| Beta-blocker | Metoprolol â Betaloc, Betaone | Angina, Heart Rate āĻ BP Control |
| Calcium Channel Blocker | Amlodipine â Amdocal | HTN āĻ Angina Management |
| Nitrate | Nitroglycerin â Nidocard, Anril | Angina Relief/Prevention |
| PPI | Esomeprazole â Maxpro MUPS, Nexum MUPS | GI Protection-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻĨāĻžāĻāϞ⧠|
āĻāĻĻāĻžāĻšāϰāĻŖ āĻšāĻŋāϏā§āĻŦā§ Clopidogrel, Amlodipine āĻ Rosuvastatin-āĻāϰ āĻāϞā§āϞāĻŋāĻāĻŋāϤ āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļāĻŋ āĻŦā§āϰā§āϝāĻžāύā§āĻĄāĻā§āϞ⧠MedEx-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϰāϝāĻŧā§āĻā§āĨ¤
āĻāĻ āϰā§āĻā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ BP āĻŦāĻŋāĻŦā§āĻāύāĻžāϝāĻŧ āύāϤā§āύ Antihypertensive āĻŦāĻž Antianginal Drug āϝā§āĻ āĻāϰāĻžāϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĻā§āĻāϝāĻŧāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
ā§Ž. Differential Diagnosis
āĻāĻ āϰā§āĻā§āϰ āϰāĻŋāĻĒā§āϰā§āĻ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦāĻŋāĻŦā§āĻā§āϝ āϰā§āĻāĻā§āϞā§:
| Possible Diagnosis | Supporting Evidence | Limitation |
| Hypertensive Heart Disease | HTN + Moderate Concentric LVH | LVH-āĻāϰ āĻ āύā§āϝāĻžāύā§āϝ āĻāĻžāϰāĻŖ āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋ |
| Chronic Coronary Syndrome | āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ IHD Diagnosis āĻāĻŦāĻ Antianginal Prescription | Angina History, ECG, Ischemia Test āĻ āύā§āĻĒāϏā§āĻĨāĻŋāϤ |
| Obstructive Coronary Artery Disease | āĻāĻŋāĻāĻŋā§āϏāĻ CAG āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž āĻāϰā§āĻā§āύ | Angiographic confirmation āύā§āĻ |
| Coronary Microvascular Dysfunction | IHD-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ | āĻā§āύ⧠diagnostic evidence āύā§āĻ |
| Hypertrophic Cardiomyopathy | LVH-āĻāϰ āĻāĻāĻāĻŋ differential | āĻŦāϰā§āϤāĻŽāĻžāύ āϰāĻŋāĻĒā§āϰā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ āϤāĻĨā§āϝ āύā§āĻ |
| Heart Failure with Preserved EF | LVH āĻāĻāĻāĻŋ associated finding āĻšāϤ⧠āĻĒāĻžāϰ⧠| HF symptoms āĻ objective filling-pressure evidence āύā§āĻ |
āĻāĻŽāĻžāϰ Clinical Interpretation
āĻāĻāĻžāύ⧠āϏāĻŦāĻā§āϝāĻŧā§ āĻāĻžāϞā§āĻāĻžāĻŦā§ āύāĻĨāĻŋāĻā§āĻā§āϤ Structural Abnormality āĻšāϞā§:
Moderate Concentric Left Ventricular Hypertrophy.
HTN-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāĻžāϝāĻŧ Hypertensive Heart Disease āĻāĻāĻāĻŋ āϝā§āĻā§āϤāĻŋāϝā§āĻā§āϤ Working DiagnosisāĨ¤
āϤāĻŦā§ IHD āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϤāĻĨā§āϝ āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
⧝. Doctor’s Diagnosis vs My Clinical Assessment
Prescribing Doctor’s Diagnosis
IHD with HTN
āĻŦāĻžāĻāϞāĻž: āĻāϏā§āĻā§āĻŽāĻŋāĻ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āϏāĻā§āĻā§ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒāĨ¤
My Working Clinical Assessment
Suspected Chronic Coronary Syndrome (IHD), with a documented history of Hypertension and Moderate Concentric Left Ventricular Hypertrophy, preserved LVEF (69%).
āĻŦāĻžāĻāϞāĻž:
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϰāύāĻŋāĻ āĻāϰā§āύāĻžāϰāĻŋ āĻšā§āĻĻā§âāϰā§āĻ; āϏāĻā§āĻā§ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āĻāϤāĻŋāĻšāĻžāϏ, āĻŦāĻžāĻŽ āĻā§āύā§āĻā§āϰāĻŋāĻāϞā§āϰ āĻĻā§āϝāĻŧāĻžāϞ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āĻĒā§āϰ⧠āĻšāĻāϝāĻŧāĻž āĻāĻŦāĻ āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āϏāĻŋāϏā§āĻā§āϞāĻŋāĻ āĻĒāĻžāĻŽā§āĻĒāĻŋāĻ āĻā§āώāĻŽāϤāĻžāĨ¤
Diagnosis Confidence Assessment
| Clinical Finding | Confidence | Justification |
| Documented HTN | 0.99 | āĻāĻŋāĻāĻŋā§āϏāĻ āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύ |
| Moderate Concentric LVH | 0.99 | Echo-āϤ⧠āϏāϰāĻžāϏāϰāĻŋ āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§ |
| Preserved LV Systolic Function | 0.99 | LVEF 69% |
| Hypertensive Heart Disease | 0.85 | HTN history + LVH |
| Suspected IHD | 0.65 | āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Diagnosis āϰāϝāĻŧā§āĻā§, āĻāĻŋāύā§āϤ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ āϤāĻĨā§āϝ āύā§āĻ |
| Confirmed Obstructive CAD | āύāĻŋāϰā§āϧāĻžāϰāĻŖāϝā§āĻā§āϝ āύāϝāĻŧ | CAG/CCTA āĻŦāĻž āĻ āύā§āϝ āϝāĻĨā§āώā§āĻ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻ |
āĻāĻā§āϞ⧠āϤāĻĨā§āϝā§āϰ āĻāĻĒāϰ āĻāĻŋāϤā§āϤāĻŋ āĻāϰ⧠āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āϰ Confidence Score, āϰā§āĻāĻāĻŋāϰ āĻĒā§āϰāĻā§āϤ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāϰ āĻĒāϰāĻŋāϏāĻāĻā§āϝāĻžāύ āύāϝāĻŧāĨ¤
Doctor’s Dx āĻāĻŦāĻ āĻāĻŽāĻžāϰ Assessment āĻāĻŋ Similar?
āĻāĻāĻļāĻŋāĻāĻāĻžāĻŦā§ SimilarāĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ HTN Diagnosis āĻāĻŦāĻ LVH-āĻāϰ āϏāĻā§āĻā§ āĻāĻŽāĻžāϰ Assessment āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
āĻĒāĻžāϰā§āĻĨāĻā§āϝ āĻšāϞā§, āĻāĻŋāĻāĻŋā§āϏāĻ IHD āϞāĻŋāĻā§āĻā§āύ, āĻāĻŋāύā§āϤ⧠āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ Confirmed IHD āĻĒā§āϰāϤāĻŋāώā§āĻ āĻž āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤ āϤāĻžāĻ āĻāĻŽāĻžāϰ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ⧠Suspected IHD āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦā§āĻļāĻŋ āϏāϤāϰā§āĻ āĻ āϝāĻĨāĻžāϝāĻĨāĨ¤
ā§§ā§Ļ. Prescription-āĻ Final Dx āĻā§ āϞāĻŋāĻāĻŦā§āύ?
āϝāĻĻāĻŋ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āύ⧠Clinical History āĻŦāĻž Confirmatory Investigation āύāĻž āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠āύāĻŋāĻā§āϰ Working Diagnosis āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
Recommended Working Diagnosis
Dx: Suspected Chronic Coronary Syndrome (IHD) with Hypertension and Moderate Concentric LVH; Preserved LVEF (69%).
āĻŦāĻžāĻāϞāĻž:
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻāϏā§āĻā§āĻŽāĻŋāĻ āĻšā§āĻĻā§âāϰā§āĻ, āϏāĻā§āĻā§ āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒ āĻ āĻŦāĻžāĻŽ āĻā§āύā§āĻā§āϰāĻŋāĻāϞā§āϰ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāϤā§āϰāĻžāϰ āĻĻā§āϝāĻŧāĻžāϞ āĻĒā§āϰ⧠āĻšāĻāϝāĻŧāĻž; āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āϏāĻŋāϏā§āĻā§āϞāĻŋāĻ āĻĒāĻžāĻŽā§āĻĒāĻŋāĻ āĻā§āώāĻŽāϤāĻž āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāĨ¤
Short Clinical Version
Dx: Suspected IHD with HTN and Concentric LVH.
āϝāĻĻāĻŋ āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠CAG, CCTA, MI āĻŦāĻž āĻ āύā§āϝ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ āĻĒāϰā§āĻā§āώāĻžāϝāĻŧ CAD āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϝāĻŧā§ āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠āϏā§āĻ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āύā§āϝāĻžāϝāĻŧā§ Established CAD/IHD āϞā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
ā§§ā§§. Doctor’s Action Plan
Step 1 â Immediate Clinical Reassessment
āĻŦāϰā§āϤāĻŽāĻžāύ BP āĻ Pulse āĻĒā§āύāϰāĻžāϝāĻŧ āĻĒāϰāĻŋāĻŽāĻžāĻĒ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
- Sitting āĻ Standing BP
- Pulse Rate
- Orthostatic Symptoms
- Chest Pain History
- Exertional Dyspnea
- Syncope āĻŦāĻž Presyncope
- āĻŦāϰā§āϤāĻŽāĻžāύ āϏāĻŦ āĻāώā§āϧ āĻāĻŦāĻ āĻĄā§āĻ
āĻŦāĻŋāĻļā§āώ āĻā§āϰā§āϤā§āĻŦ: āϰā§āĻā§ āϝāĻĻāĻŋ āĻāĻāύ⧠Olmesan, Betaloc āĻ Nidocard āĻā§āϰāĻšāĻŖ āĻāϰā§āύ āĻāĻŦāĻ BP āĻāĻŽ āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠Prescribing Cardiologist-āĻāϰ āĻĻā§āϰā§āϤ Medication Review āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
āĻŦāϰā§āϤāĻŽāĻžāύ⧠āϤā§āĻŦā§āϰ āĻŦā§āĻā§ āĻŦā§āϝāĻĨāĻž, āĻļā§āĻŦāĻžāϏāĻāώā§āĻ, āĻ āĻā§āĻāĻžāύ āĻšāĻāϝāĻŧāĻž āĻŦāĻž āĻā§āϰā§āϤāϰ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻĨāĻžāĻāϞ⧠āĻāϰā§āϰāĻŋ āĻŦāĻŋāĻāĻžāĻā§ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 2 â Further Investigations
| Investigation | Purpose |
| 12-lead ECG | Ischemic Change, Arrhythmia, LVH |
| Repeat Echocardiography, if clinically indicated | āĻŦāϰā§āϤāĻŽāĻžāύ LV Structure āĻ Function |
| Fasting Lipid Profile | LDL-C āĻāĻŦāĻ Statin Intensity |
| HbA1c | Diabetes Screening |
| CBC | Anemia āĻ Baseline Hemoglobin |
| Serum Electrolytes | Sodium, Potassium |
| Serum Creatinine + eGFR | Renal Function, āĻŦāĻŋāĻļā§āώāϤ Contrast āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ |
| Urine ACR | Hypertensive Kidney Damage āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
| CCTA / Functional Imaging | Clinical Likelihood āĻ āύā§āϝāĻžāϝāĻŧā§ CAD Evaluation |
| CAG | Cardiologist-āĻāϰ Risk Assessment āĻ Indication āĻ āύā§āϝāĻžāϝāĻŧā§ |
CAG-āĻāϰ āĻāĻā§ renal function āĻ contrast-related risks āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Step 3 â Medication Optimization
āĻŦāϰā§āϤāĻŽāĻžāύ Prescription Review āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻŦāĻŋāĻļā§āώ āĻāϰā§:
Olmesartan + Metoprolol + Nitroglycerin
āĻāĻ āϏāĻŽāύā§āĻŦāϝāĻŧā§ BP āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāĻŽāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰāϝāĻŧā§āĻā§āĨ¤
āĻ āĻāĻžāĻĄāĻŧāĻž āύāĻŋāĻļā§āĻāĻŋāϤ CAD āĻĨāĻžāĻāϞ⧠Statin Intensity āĻāĻŦāĻ Aspirin-āĻāϰ indication āĻ bleeding risk āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Step 4 â Referral
Refer to: Consultant Cardiologist / Interventional Cardiologist
āĻāĻžāϰāĻŖ:
- Suspected IHD-āĻāϰ āϝāĻĨāĻžāϝāĻĨ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ
- CAG Indication āύāĻŋāϰā§āϧāĻžāϰāĻŖ
- Low BP āĻāĻŦāĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ
- LVH āĻ Hypertension Management
Referral Note:
A 56-year-old female with a documented history of hypertension and suspected ischemic heart disease. Previous echocardiography revealed moderate concentric LVH with preserved LVEF (69%). BP was recorded as 95/63 mmHg. Kindly evaluate the indication for coronary angiography, assess current cardiovascular status, and review antianginal and antihypertensive therapy.
⧧⧍. Overview / Summary
| Clinical Parameter | Final Assessment |
| Doctor’s Diagnosis | IHD with HTN |
| Main Structural Finding | Moderate Concentric LVH |
| LVEF | 69%, preserved |
| Current Recorded BP | 95/63 mmHg |
| Recorded Pulse | 74 bpm |
| CXR | Cardiomegaly |
| Confirmed CAD | Not established from available records |
| Treatment Plan | CAG |
| Major Medication Concern | Possible BP-lowering effects of multiple drugs |
| Referral | Cardiologist |
| Recommended Working Dx | Suspected IHD with HTN and Moderate Concentric LVH |
āĻāϰā§āĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻ āϏāĻāĻāϤāĻŋ: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāĻĒāϰ⧠āϤāĻžāϰāĻŋāĻ 05/01/2026, āĻāĻŋāύā§āϤ⧠āϏāĻŋāϞā§āϰ āϤāĻžāϰāĻŋāĻ 05 Jan 2025 āĻĻā§āĻāĻž āϝāĻžāĻā§āĻā§āĨ¤ Echo-āϰ āϤāĻžāϰāĻŋāĻ 05/01/2024āĨ¤ āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āύāĻĨāĻŋ āĻĻāĻŋāϝāĻŧā§ āϤāĻžāϰāĻŋāĻāĻā§āϞ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
ā§§ā§Š. Reference List
Standard Medical Textbooks
- Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill. Sections on Chronic Coronary Disease, Hypertension and Cardiovascular Diagnosis.
- Davidson’s Principles and Practice of Medicine. 24th Edition. Elsevier. Cardiovascular Disease chapters.
- Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 12th Edition. Elsevier. Sections on Stable Ischemic Heart Disease and Hypertensive Heart Disease.
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw Hill. Sections on Antihypertensive, Antianginal, Antiplatelet and Lipid-lowering Drugs.
International Guidelines
1. ESC Guidelines 2024
Vrints CJM, et al. 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.
European Heart Journal. 2024;45:3415â3537.
DOI: 10.1093/eurheartj/ehae177.
2. AHA/ACC Guideline 2023
Virani SS, et al. 2023 AHA/ACC Multisociety Guideline for the Management of Patients with Chronic Coronary Disease.
Circulation. 2023;148:e9âe119.
DOI: 10.1161/CIR.0000000000001168.
3. ESC Guidelines 2024 â Hypertension
2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension.
European Society of Cardiology.
Drug Reference
MedEx Bangladesh: āĻāώā§āϧā§āϰ Generic Name, Therapeutic Class, āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļāĻŋ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ, Strength āĻāĻŦāĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āĻŽā§āϞā§āϝ MedEx-āĻāϰ āϏāĻāĻļā§āϞāĻŋāώā§āĻ Brand Pages āĻĨā§āĻā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ āĻŦāĻžāĻāĻžāϰāĻŽā§āϞā§āϝ āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
â Final Clinical Assessment
Suspected Chronic Coronary Syndrome (IHD) with Hypertension and Moderate Concentric LVH; Preserved LV Systolic Function (LVEF 69%).
āϏāĻŦāĻā§āϝāĻŧā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ: āϰā§āĻā§āϰ LVH āĻāĻŦāĻ HTN-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āĻšāϞā§āĻ āĻāϰā§āύāĻžāϰāĻŋ āĻāϰā§āĻāĻžāϰāĻŋāϤ⧠āĻŦā§āϞāĻā§āĻ āĻŦāĻž Myocardial Ischemia āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϝāĻŧāύāĻŋāĨ¤ āϤāĻžāĻ CAG-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧāϤāĻž āĻāĻŦāĻ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻāĻŽ āϰāĻā§āϤāĻāĻžāĻĒā§āϰ āϏāĻā§āĻā§ Antianginal āĻ Antihypertensive āĻāώā§āϧāĻā§āϞā§āϰ āϏāĻŽā§āĻĒāϰā§āĻ Cardiologist-āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻžāĻ āĻĒāϰāĻŦāϰā§āϤ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāĻĻāĻā§āώā§āĻĒāĨ¤
Md.Rafiqul Islam Lipu